Experimental cancer vaccine Amivantamab eliminates tumors in some patients, The Guardian reports. In a trial, tumors shrank/disappeared in 43 of 102 head & neck cancer patients who failed other treatments.
Experimental cancer vaccine Amivantamab completely eliminated tumors in some patients within weeks, according to The Guardian. The study conducted across 11 countries showed tumors shrank or disappeared in 43 out of 102 head and neck cancer patients who had failed other treatments.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Hubs
Briefings
More story pages
Suspected Ebola cases surpass 1,000 in latest outbreak
Suspected Ebola cases have exceeded 1,000 in the latest outbreak, according to reports.
Akeso lung cancer drug extends survival 15% over immunotherapy in China trial, Reuters reports. The bispecific antibody outperformed standard treatment in a Phase 3 study.
Akeso Biopharma's lung cancer drug demonstrated a 15% improvement in overall survival compared to immunotherapy in a China-based trial, according to Reuters.
Congo and Uganda confirm 263 Ebola cases, 43 deaths, Africa CDC reports.
Congo and Uganda report 263 confirmed Ebola cases with 43 deaths, Africa CDC says.
Revolution Medicines' pancreatic cancer drug daraxonrasib nearly doubles survival, delays symptoms for months in trial
Revolution Medicines Inc.'s experimental pancreatic cancer drug daraxonrasib delayed painful symptoms for months and nearly doubled survival.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.